碧蓝羽毛
Lv2
140 积分
2022-08-24 加入
-
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)
18天前
已完结
-
Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms
1个月前
已关闭
-
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
3个月前
已完结
-
Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract
3个月前
已完结
-
Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial (075)
3个月前
已完结
-
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
3个月前
已完结
-
Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas
4个月前
已完结
-
The biology and management of non-small cell lung cancer
5个月前
已完结
-
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
5个月前
已完结
-
Resistance to Immunotherapy: Mechanisms and Means for Overcoming
5个月前
已完结